Planned in the near future.
The ISO-registered production partner for the Diastroke ELISA systems is Mabtech, Sweden.
Know your symptoms
The enzyme GPBB enters the bloodstream when cerebral ischemia, i.e. insufficient oxygen supply to the brain, occurs. Such ischemia leads in the long term to necrosis (cell death) of the affected cells and / or ultimately to infarction (stroke). The detection of GPBB in the blood therefore provides information about the potential presence of a stroke and thus makes a decisive contribution to the diagnosis of stroke patients. So far, no biomarker is known in the stroke area that can reliably detect it shortly after the onset of the infarction.
The previous diagnosis is based solely on the interpretation of the symptoms and the use of complex, time-consuming and costly imaging methods (e.g. computed tomography). When diagnosing a stroke, time is a decisive factor for the success of the treatment.
GPBB can be detected at an early stage, namely within the first hour. Especially in the case of a stroke, this is a decisive advantage, as a quick and accurate diagnosis can save lives.